Clinical trial
A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
NCT01441388 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1B, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Crizotinib (PF-02341066) Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- December 31, 2011
- Completion date
- November 30, 2013
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.